FAQ

Clients & Partners

Can I send you my target directly?

Yes. Most of our projects begin with a well-characterized target — either a sequence (for nucleic acids or peptides) or a structure (PDB, AlphaFold, cryo-EM models). We’ll assess feasibility and jointly define the design objectives before starting.

Do you offer in-house synthesis and QC?

We collaborate with trusted synthesis partners. Our base package includes aptamer synthesis (pilot batch), HPLC purification, MS validation, and a technical report. All sequences are tested via fluorescence anisotropy to assess binding. SPR and advanced QC can be arranged, but are not part of the standard offer.

What is the cost of the standard package?

Our standard package — including AI-based design, synthesis, quality control (HPLC + MS), and fluorescence anisotropy binding assessment — ranges between €4000 and €5000. Pricing may vary slightly based on target complexity and synthesis specifications.

How do you ensure aptamer novelty?

We use diverse generative strategies (transformers, probabilistic sampling, latent space navigation) combined with filtering based on motif, entropy, and GC-content constraints. Final sequences are checked against internal databases to ensure they are not redundant or derived from prior public sequences.

How long does a typical project take?

It depends on the scope. For a single-target aptamer design with validation, timelines typically range from 4 to 8 weeks. Multi-target or iterative campaigns may extend further. We prioritize fast convergence with high interpretability.

Do I retain IP over the final aptamer sequences?

Yes. Unless otherwise agreed, all deliverables — including aptamer sequences and experimental data — are transferred to the client with full rights. We do not retain commercial rights on commissioned work.

Can we run a pilot before committing to a larger project?

Absolutely. We often begin with exploratory pilots that test feasibility, target behavior, or initial binding results. These projects are compact and structured to reduce upfront risk while generating actionable insights.

Do you support therapeutic applications?

Yes, provided there is a clear biological rationale. We design aptamers for diagnostics, imaging, and targeted delivery. Therapeutic-grade development (e.g., chemical modifications, in vivo testing) requires collaboration with CROs or internal teams.

What if my protein has no known structure?

We can use AlphaFold or homology modeling to approximate the target structure, enabling docking and site prediction. If even sequence data is limited, we may advise waiting or supplying more background data before proceeding.

Do you offer exclusivity over designed aptamers?

Yes. Each design project is exclusive to the client and target. We do not reuse or resell sequences developed under a custom project.

Do you work under confidentiality or NDA?

Yes. We are open to signing mutual NDAs at the start of any discussion. Confidentiality and data security are core principles of our workflow.

What are the ideal use cases for your platform?

Our platform is best suited for high-affinity binder discovery in diagnostics, targeted delivery, and research tools. It performs best when paired with defined targets and rapid feedback cycles.

Still unsure?
Reach out. We’ll reply directly — no gatekeeping, no vague answers. Just honest guidance.